$6.20
-0.03-0.48%
At Close: -
$6.18
-0.02-0.32%
After Hours: 5:03 PM EDT
15 minutes delayed
Comments
Loading...
Black Diamond Therapeutic
BDTXNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Black Diamond Therapeutic (NASDAQ:BDTX) Stock, Analyst Ratings, Price Targets, Forecasts
Black Diamond Therapeutics Inc has a consensus price target of $12.25 based on the ratings of 4 analysts. The high is $16 issued by Wedbush on April 8, 2024. The low is $10 issued by Stifel on June 30, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on July 3, 2024, June 7, 2024, and May 16, 2024, respectively. With an average price target of $11.33 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 83.39% upside for Black Diamond Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Wedbush
Stifel
1calculated from analyst ratings
Analyst Ratings for Black Diamond Therapeutic
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | 94.17% | Piper Sandler | Joseph Catanzaro | $12 → $12 | Maintains | Overweight | Get Alert |
| 06/07/2024 | Buy Now | 77.99% | HC Wainwright & Co. | Robert Burns | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 77.99% | HC Wainwright & Co. | Robert Burns | $12 → $11 | Maintains | Buy | Get Alert |
| 04/08/2024 | Buy Now | 158.9% | Wedbush | Robert Driscoll | $10 → $16 | Maintains | Outperform | Get Alert |
| 03/18/2024 | Buy Now | 94.17% | HC Wainwright & Co. | Robert Burns | $11 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 61.81% | Wedbush | Robert Driscoll | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 11/22/2023 | Buy Now | 77.99% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 61.81% | Wedbush | Robert Driscoll | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 07/14/2023 | Buy Now | 77.99% | Piper Sandler | Joseph Catanzaro | → $11 | Initiates | → Overweight | Get Alert |
| 06/30/2023 | Buy Now | 61.81% | Stifel | Bradley Canino | $2 → $10 | Upgrade | Hold → Buy | Get Alert |
| 06/28/2023 | Buy Now | 77.99% | HC Wainwright & Co. | Robert Burns | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 06/27/2023 | Buy Now | -67.64% | Stifel | Bradley Canino | → $2 | Reiterates | Hold → Hold | Get Alert |
| 06/27/2023 | Buy Now | 61.81% | Wedbush | Robert Driscoll | → $10 | Upgrade | Neutral → Outperform | Get Alert |
| 05/10/2023 | Buy Now | -51.46% | Wedbush | Robert Driscoll | → $3 | Reiterates | → Neutral | Get Alert |
| 03/29/2022 | Buy Now | — | Wedbush | Robert Driscoll | — | Downgrade | Outperform → Neutral | Get Alert |
| 03/22/2022 | Buy Now | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
| 03/18/2022 | Buy Now | -35.28% | Stifel | Bradley Canino | $10 → $4 | Maintains | Hold | Get Alert |
| 09/30/2021 | Buy Now | 61.81% | Stifel | Bradley Canino | — | Initiates | → Hold | Get Alert |
FAQ
What is the target price for Black Diamond Therapeutic (BDTX) stock?
The latest price target for Black Diamond Therapeutic (NASDAQ:BDTX) was reported by Piper Sandler on July 3, 2024. The analyst firm set a price target for $12.00 expecting BDTX to rise to within 12 months (a possible 94.17% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Black Diamond Therapeutic (BDTX)?
The latest analyst rating for Black Diamond Therapeutic (NASDAQ:BDTX) was provided by Piper Sandler, and Black Diamond Therapeutic maintained their overweight rating.
When was the last upgrade for Black Diamond Therapeutic (BDTX)?
The last upgrade for Black Diamond Therapeutics Inc happened on June 30, 2023 when Stifel raised their price target to $10. Stifel previously had a hold for Black Diamond Therapeutics Inc.
When was the last downgrade for Black Diamond Therapeutic (BDTX)?
The last downgrade for Black Diamond Therapeutics Inc happened on March 29, 2022 when Wedbush changed their price target from N/A to N/A for Black Diamond Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Black Diamond Therapeutic (BDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Black Diamond Therapeutic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Black Diamond Therapeutic was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
Is the Analyst Rating Black Diamond Therapeutic (BDTX) correct?
While ratings are subjective and will change, the latest Black Diamond Therapeutic (BDTX) rating was a maintained with a price target of $12.00 to $12.00. The current price Black Diamond Therapeutic (BDTX) is trading at is $6.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.